Wednesday, 22 March 2017

EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

Latest news -- http://www.prnewswire.com/news-releases/engeneic-doses-first-patient-in-us-phase-1-clinical-study-of-targeted-edv-nanocells-in-recurrent-glioblastoma-multiforme-300426888.html

1 comment:

  1. A brief description of this therapy here:
    https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=782631

    First in human case study here:
    https://www.ncbi.nlm.nih.gov/pubmed/26279503

    An interesting thing about doxorubicin is that it's a bona fide inducer of immunogenic cell death, which means it kills cells in such a way that the dying cell releases danger signals that arouse an immune response.
    http://journal.frontiersin.org/article/10.3389/fimmu.2015.00187/full

    ReplyDelete